Overview
Paul Mueller Q3 net sales fell slightly compared to the same period last year
Net income for Q3 declined due to challenges in pharmaceutical projects
Company announces tender offer at $485 per share ending November 21, 2025
Result Drivers
PHARMACEUTICAL PROJECT CHALLENGES - Co faced difficulties in fabrication tasks for two large pharmaceutical jobs, impacting Q3 earnings
BACKLOG INCREASE - U.S. backlog rose significantly, driven by pharmaceutical clients in the Industrial Equipment segment
EUROPEAN OPERATIONS - European backlog nearly doubled, indicating growth in that region
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
9M Sales | $192.85 mln | ||
9M Net Income | $21.43 mln | ||
9M Gross Profit | $61.71 mln | ||
9M Operating Income | $26.54 mln |
Press Release: ID:nGNX6pK9MX
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

